Table 1.

CRC cell lines and drugs used in the study and their characterization [33,34,35,36,37].

Cell Line	Duke’s Type	Cell Status	MSI/CIN	CIMP	Mutations/Deregulations
DLD1	C	undifferentiated	MSI	CIMP +	APC l1417fs, R2166, KRAS G13D, PIK3CA E545K; D549N, TP53 S241F
HCT116	A	undifferentiated	MSI	CIMP +	KRAS G13D, PIK3CA H1047R
SW620	C	undifferentiated	MSS; CIN pos46	CIMP −	APC Q1338, KRAS G12V, TP53 R273H; P309S
LS174T	B	colon-like	MSI	CIMP −	KRAS G12D, PIK3CA H1047R, BRAF p.D211Gc
Drug		Chemical Formula	IUPAC Chemical Nomenclature		Abb.
folinic acid (leucovorin)		C20H23N7O7	(2S)-2-[[4-[(2-amino-5-formyl-4-oxo-3,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid		FA
5-fluorouracil		C4H3FN2O2	5-fluoro-1H-pyrimidine-2,4-dione		FU
oxaliplatin		C8H12N2O4Pt	[(1R,2R)-2-azanidylcyclohexyl]azanide;oxalate;platinum(4+)		OX
irinotecan		C33H38N4O6	[(19S)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[1 1.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-7-yl] 4-piperidin-1-ylpiperidine-1-carboxylate		IRI
7-Ethyl-10-hydroxycamptothecin *		C22H20N2O5	(19S)-10,19-diethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaene-14,18-dione		SN

MSI: microsatellite instability; MSS: microsatellite stability; CIN: chromosomal instability, CIMP: CpG island methylator phenotype; Abb.: abbreviation; IUPAC: International Union of Pure and Applied Chemistry; * active metabolite of IRI, also known as SN38.